ATXS — Astria Therapeutics Share News
0.000.00%
Last trade - 00:00- $718.13m
- $585.73m
Astria Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: Astria Therapeutics Picks Ypsomed’s YpsoMate as Injection Device for STAR-0215
Astria Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Astria Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Astria Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule
Brief: Astria Therapeutics Increases Board Size To Nine
Brief: Astria Therapeutics Appoints Sunil Agarwal To Its Board
U.S. RESEARCH ROUNDUP-Altair Engineering, Applied Therapeutics, Microsoft
Brief: Astria Therapeutics Announces Positive Initial Proof-of-Concept Results From ALPHA-STAR Phase 1b/2 Trial
U.S. RESEARCH ROUNDUP-American Tower, Lennar, Nike
Brief: Astria Therapeutics Announces Pricing Of $125 Million Underwritten Offering
Brief: TCG Crossover GP II Reports 9.9% Passive Stake In Astria Therapeutics
Brief: Astria Therapeutics Files For Mixed Shelf Of Up To $500 Mln - SEC Filing
U.S. RESEARCH ROUNDUP-Domino's Pizza, Duolingo, Tractor Supply Co
Brief: Astria Therapeutics Announces Pricing Of $64 Million Underwritten Offering
Brief: Astria Therapeutics Announces Exclusive Worldwide License Agreement With Ichnos Sciences For Ox40 Portfolio
Astria Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Astria Therapeutics Q2 EPS USD -0.45